Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Laughon Matthew M, Thomas Sonia M, Watterberg Kristi L, Kennedy Kathleen A, Keszler Martin, Ambalavanan Namisavayam, Davis Alexis S, Slaughter Jonathan L, Guillet Ronnie, Colaizy Tarah T, Cotten C Michael, Dhawan Megan A, Bose Carl L, Talbert Jennifer, Smucny Sarah, Benitz William E, Rysavy Matthew A, Ohls Robin K, Baserga Mariana C, DeMauro Sara B, Jaleel Mambarambath, Jackson Wesley M, Carlo Waldemar A, Puopolo Karen M, Hibbs Anna Maria, Katheria Anup, Sánchez Pablo J, D'Angio Carl T, Patel Ravi M, Johnson Beth Ann, Chock Valerie Y, Bhatt Abhay J, Merhar Stephanie L, Moore Ryan, Laptook Abbot R, Ghavam Sarvin, Fuller Janell, Vyas-Read Shilpa, Kicklighter Stephen D, Steinbrekera Baiba, Anderson Kathryn, Chandrasekharan Praveen K, Wyckoff Myra H, Montoya Cassandra, Das Abhik, Do Barbara, Chang Samantha, Higgins Rosemary D, Walsh Michele C, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network
Аннотация
OBJECTIVE: To determine whether expectant management compared with active treatment of a protocol-defined PDA in preterm infants decreases the incidence of death or bronchopulmonary dysplasia (BPD).
DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial including infants born at 22 to 28 weeks' gestation and diagnosed with a protocol-defined PDA between the age of 48 hours and 21 days at screening. The trial was conducted from December 2018 to December 2024 at 33 hospitals within the National Institute of Child Health and Human Development Neonatal Research Network. The final date of follow-up was June 2025.
INTERVENTIONS: Infants with PDA were randomized to expectant management (n = 242) or active treatment (n = 240; acetaminophen, ibuprofen, or indomethacin) to close the PDA.
MAIN OUTCOMES AND MEASURES: The primary outcome was death or BPD at 36 weeks' postmenstrual age. The secondary outcomes included the components of the primary outcome and other morbidities of prematurity.
RESULTS: A total of 482 infants were randomized (median gestational age, 25 weeks [IQR, 24 to 27 weeks]; median birth weight, 760 g [IQR, 620 to 935 g]). The trial was stopped for futility and safety after the 50% interim analysis for the primary outcome due to higher survival in the expectant management group. The incidence of death or BPD was 80.9% (195/241) of infants in the expectant management group vs 79.6% (191/240) of infants in the active treatment group (adjusted risk difference, 1.2% [95% CI, -5.7% to 8.1%]; P = .73). The incidence of death before 36 weeks' postmenstrual age was 4.1% (10/241) of infants in the expectant management group vs 9.6% (23/240) of infants in the active treatment group (adjusted risk difference, -5.6% [95% CI, -10.1% to -1.2%]; P = .01). Infections resulting in death occurred in 0.8% (2/241) of infants in the expectant management group vs 3.8% (9/240) of infants in the active treatment group.
CONCLUSIONS AND RELEVANCE: In extremely preterm infants with a protocol-defined PDA, death or BPD did not differ between the expectant management group and the active treatment group. Survival was substantially higher with expectant management.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03456336.